1 |
NCT02188459 |
Recruiting |
Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women |
- Smoking
- Nicotine Dependence
|
|
Interventional |
Phase 2 |
- Henry Kranzler
- University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of cigarettes smoked by medication group over 10 week treatment phase.
- Frequency of moderate or severe side effects.
- Birth outcomes obtained from clinical records.
- Smoking frequency after 10 weeks treatment phase.
|
360 |
Female |
18 Years and older (Adult, Senior) |
NCT02188459 |
820364 |
BIBS |
October 2014 |
December 2020 |
January 2021 |
July 11, 2014 |
November 13, 2017 |
|
- Christiana Care Health System
Newark, Delaware, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States - Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
2 |
NCT02432066 |
Not yet recruiting |
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions |
|
- Drug: GTS-21
- Drug: Placebo
|
Interventional |
Phase 2 |
- University of Florida
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Reported Nicotine Use from baseline at weeks 1, 2, 3, 4, 5, 6, 7, 8
- Change in Carbon Monoxide (CO) from baseline at weeks 5, 8
- Change in Urine Cotinine (COT) from baseline at weeks 5, 8
- (and 63 more...)
|
60 |
All |
25 Years to 60 Years (Adult) |
NCT02432066 |
IRB201500393-N Nixon2015 NIH-pending |
|
September 29, 2018 |
December 29, 2018 |
December 29, 2020 |
May 1, 2015 |
April 5, 2018 |
|
- Neurocognitive Lab, University of Florida, Department of Psychiatry
Gainesville, Florida, United States
|
3 |
NCT02106637 |
Recruiting |
Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Patients After ACS |
- Acute Coronary Syndrome
- Smoking Cessation
|
- Drug: Varenicline
- Drug: placebo
|
Interventional |
Not Applicable |
- Sheba Medical Center
- Hadassah Medical Organization
- Barzilai Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Primary efficacy and Safety endpoint:
- Secondary Outcomes - Weight change
- Smoking abstinence at 1 and 6 months
|
300 |
All |
21 Years and older (Adult, Senior) |
NCT02106637 |
CHAMPIX (CHANTIX) |
|
October 2016 |
August 2018 |
December 2018 |
April 8, 2014 |
December 5, 2017 |
|
- Sheba Medical Center
Ramat Gan, Israel
|
4 |
NCT02126124 |
Recruiting |
Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation. |
|
- Device: Sham Treatment
- Device: Active dTMS Treatment
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Continuous Quit Rate
- Number of Cigarettes Smoked Per Day
|
224 |
All |
22 Years to 70 Years (Adult, Senior) |
NCT02126124 |
BR-SMOK-01 |
|
April 2014 |
December 2018 |
December 2018 |
April 29, 2014 |
January 25, 2018 |
|
- Pacific Institute of Medical Research
Los Angeles, California, United States - University of California - San Diego Medical Center
San Diego, California, United States - TMS Center of Colorado
Denver, Colorado, United States - (and 15 more...)
|
5 |
NCT02399709 |
Recruiting |
Trial to Evaluate the Efficacy of Simvastatin for Smoking Cessation |
|
- Drug: simvastatin
- Drug: Placebo
|
Interventional |
Phase 2 |
- Poitiers University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Self-reported number of cigarettes smoked
- Self-reported continuous abstinence during the last 4 weeks of the 3 months of treatment with simvastatin versus placebo
- Expired air carbon monoxide ≤ 8 ppm
- (and 2 more...)
|
100 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02399709 |
ADDICSTATINE |
ADDICSTATINE |
March 2015 |
December 2015 |
|
March 26, 2015 |
October 11, 2016 |
|
- Poitiers University Hospital
Poitiers, France
|
6 |
NCT02575183 |
Recruiting |
Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation |
|
- Drug: Varinecline (Chantix)
- Drug: Placebo (for Varenicline)
- Behavioral: Behavioral Therapy
|
Interventional |
Phase 4 |
- American University of Beirut Medical Center
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Prolonged abstinence from waterpipe smoking at three months post-cessation
- Continuous abstinence prevalence
- Seven-day point prevalence abstinence
- (and 7 more...)
|
152 |
All |
18 Years and older (Adult, Senior) |
NCT02575183 |
WI195422 |
|
August 31, 2016 |
September 1, 2018 |
December 1, 2018 |
October 14, 2015 |
January 10, 2018 |
|
- American University of Beirut Medical Center
Beirut, Lebanon - American University of Beirut Medical Center
Beirut, Lebanon
|
7 |
NCT02685072 |
Recruiting |
Progesterone Augmentation of Nicotine Replacement Therapy Study |
|
- Drug: Progesterone (200 mgs BID)
- Drug: Placebo
|
Interventional |
Phase 4 |
- Yale University
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- 7-day point prevalence of smoking abstinence
- Carbon monoxide <10 ppm
- Change in Stroop measure of inhibitory function
- (and 5 more...)
|
50 |
Female |
18 Years to 45 Years (Adult) |
NCT02685072 |
1504015618 R21CA198187 |
PANS |
April 7, 2016 |
July 2018 |
September 1, 2018 |
February 18, 2016 |
January 17, 2018 |
|
- Yale School of Medicine, Department of Psychiatry
New Haven, Connecticut, United States
|
8 |
NCT03000387 |
Recruiting |
Personalized Dosing of Nicotine Replacement (NRT to Effect) |
- Tobacco Use Disorder
- Nicotine Dependence
|
- Drug: Nicotine Patch
- Drug: Placebos
|
Interventional |
Phase 3 |
- Centre for Addiction and Mental Health
- Canadian Cancer Society Research Institute (CCSRI)
- Ottawa Heart Institute Research Corporation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Short term continuous abstinence
- Long term continuous abstinence
|
500 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03000387 |
039/2015 |
|
January 23, 2018 |
December 2020 |
June 2021 |
December 22, 2016 |
April 6, 2018 |
|
- University of Ottawa Heart Institute
Ottawa, Ontario, Canada - Center for Addcition and Mental Health
Toronto, Ontario, Canada
|
9 |
NCT01842334 |
Recruiting |
D-cycloserine (DCS) Pretreatment + Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation (DCS) |
- Nicotine Dependence
- Smoking Cessation
|
- Behavioral: Cognitive Behavioral Therapy
- Drug: Nicotine Replacement Therapy
|
Interventional |
Phase 1 Phase 2 |
- Mclean Hospital
- American Lung Association
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in cigarette smoking in treatment seeking nicotine dependent outpatients
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT01842334 |
2012P001707 |
DCS |
April 2013 |
August 2017 |
August 2017 |
April 29, 2013 |
April 27, 2017 |
|
- McLean Hospital
Belmont, Massachusetts, United States
|
10 |
NCT02634281 |
Recruiting |
Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation? |
|
- Drug: Varenicline
- Drug: placebo
|
Interventional |
Phase 4 |
- Shaare Zedek Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Continuous abstinence
- smoking reduction
- Decline in pulmonary function
- (and 3 more...)
|
242 |
All |
18 Years and older (Adult, Senior) |
NCT02634281 |
0239-15-SZMC |
|
February 2016 |
May 2018 |
July 2018 |
December 18, 2015 |
October 31, 2017 |
|
- Shaare Zedek Medical center
Jerusalem, Israel
|
11 |
NCT02412631 |
Recruiting |
Addressing Post Cessation Weight Gain |
|
- Drug: lorcaserin
- Drug: Varenicline
- Drug: Placebo
|
Interventional |
Phase 2 Phase 3 |
- Mayo Clinic
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Post cessation weight gain
- Waist circumference
- Smoking abstinence
|
100 |
All |
18 Years to 65 Years (Adult) |
NCT02412631 |
15-005230 1K23DA037299-01A1 14-005682 |
|
June 2016 |
August 2020 |
December 2020 |
April 9, 2015 |
April 12, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
12 |
NCT02888444 |
Not yet recruiting |
Smoking Relapse Prevention Among COPD Ex-smokers |
- Chronic Obstructive Pulmonary Disease
- Smoking Cessation
|
- Drug: Varenicline
- Behavioral: Behavioural support
- Drug: Placebo
|
Interventional |
Phase 3 |
- University of Auckland, New Zealand
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Continuous abstinence
- 7-day point prevalence abstinence
- Time to lapse
- (and 7 more...)
|
262 |
All |
18 Years and older (Adult, Senior) |
NCT02888444 |
113 |
SPACE |
May 2017 |
April 2019 |
April 2019 |
September 5, 2016 |
May 12, 2017 |
|
|
13 |
NCT02797275 |
Recruiting |
Secondhand Smoke Respiratory Health Study |
- Secondhand Smoke
- Air Trapping
- Tobacco
- (and 3 more...)
|
- Drug: Albuterol
- Drug: Placebo
|
Interventional |
Phase 4 |
- University of California, San Francisco
- Flight Attendant Medical Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Maximum Oxygen Consumption (Max VO2)
- Airflow Limitation
- Dynamic Hyperinflation
- (and 3 more...)
|
225 |
Female |
40 Years to 80 Years (Adult, Senior) |
NCT02797275 |
SHS |
|
March 2013 |
May 2017 |
|
June 13, 2016 |
July 6, 2016 |
|
- VA Medical Center
San Francisco, California, United States - University of California San Francisco
San Francisco, California, United States
|
14 |
NCT02360631 |
Recruiting |
Advancing Tobacco Use Treatment for African American Smokers |
|
- Drug: Chantix
- Drug: Placebo
|
Interventional |
Phase 4 |
- Lisa Sanderson Cox, PhD
- National Institute on Drug Abuse (NIDA)
- University of Kansas Medical Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT02360631 |
STUDY00000721 R01DA035796 |
KIS-IV |
July 2015 |
December 2018 |
December 2018 |
February 10, 2015 |
October 12, 2017 |
|
- University of Kansas Medical Center
Kansas City, Kansas, United States - Swope Health Central
Kansas City, Missouri, United States
|
15 |
NCT02560324 |
Recruiting |
Effect of Ramelteon on Smoking Abstinence |
|
- Drug: Ramelteon
- Drug: Placebo
|
Interventional |
Phase 2 |
- University of Pennsylvania
- National Institute on Drug Abuse (NIDA)
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Total number of smoke-free days (biochemically verified) during each 5-day quit assessment.
- Subjective sleep disturbance
- Objective sleep disturbance
- Side effects of ramelteon
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT02560324 |
823286 R21DA040902 |
RAP |
September 2015 |
August 2018 |
September 2018 |
September 25, 2015 |
September 15, 2017 |
|
- Center for Interdisciplinary Research on Nicotine Addiction, School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
16 |
NCT03309943 |
Recruiting |
Neurobehavioral Substrates of Proranolol's Effects on Drug Cue Reactivity |
|
- Drug: Propranolol
- Drug: Placebo
|
Interventional |
Phase 4 |
- Duke University
- National Institutes of Health (NIH)
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- fMRI BOLD Activation
- fMRI Connectivity
- Craving
- Number of puffs taken during ad lib smoking period
|
50 |
All |
18 Years to 55 Years (Adult) |
NCT03309943 |
Pro00083809 |
ProCue |
January 16, 2018 |
August 31, 2018 |
August 31, 2018 |
October 16, 2017 |
January 24, 2018 |
|
- Duke University School of Medicine
Durham, North Carolina, United States
|
17 |
NCT03382106 |
Recruiting |
Smoking Cessation and Functional CT Assessment |
|
- Drug: Sildenafil 20 MG
- Drug: Placebo Oral Tablet
|
Interventional |
Phase 4 |
- Eric A. Hoffman
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Iowa
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Dual energy CT determined pulmonary blood volume will be measured in a total of 80 smoking cessation subjects.
|
80 |
All |
25 Years to 65 Years (Adult) |
NCT03382106 |
201706713 R01HL130883 |
|
March 19, 2018 |
February 2023 |
December 2023 |
December 22, 2017 |
March 29, 2018 |
|
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
18 |
NCT03264313 |
Recruiting |
Deep Transcranial Magnetic Stimulation (dTMS) to Induce Smoking Cessation |
- Smoking Cessation
- Transcranial Magnetic Stimulation
|
- Device: Deep Transcranial Magnetic Stimulation
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Decrease on Monoximetry level
- Changes on Cotinine blood level
|
100 |
All |
22 Years to 70 Years (Adult, Senior) |
NCT03264313 |
35068014400000068 |
SmokCessdTMS |
January 16, 2017 |
January 2019 |
January 2020 |
August 29, 2017 |
September 5, 2017 |
|
- Incor - Instituto do Coração do HCFMUSP
São Paulo, Brazil
|
19 |
NCT03444298 |
Not yet recruiting |
A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults |
|
- Drug: Gamma Tocopherol
- Drug: Placebo
|
Interventional |
Phase 2 |
- University of North Carolina, Chapel Hill
- National Institute of Environmental Health Sciences (NIEHS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- change in sputum % neutrophils with WSP exposure
- change in absolute neutrophil count (ANC) in peripheral blood with WSP exposure
|
20 |
All |
18 Years to 45 Years (Adult) |
NCT03444298 |
17-2303 5R01ES025124 |
SmokeyT |
May 2018 |
February 2021 |
March 2021 |
February 23, 2018 |
April 18, 2018 |
|
|
20 |
NCT02551692 |
Recruiting |
Effects of Smoking Environments on Craving and Smoking (CameraCue2.0) |
|
- Drug: Nicotine Patch
- Drug: Varenicline
- Drug: Placebo Nicotine Patch
- Drug: Placebo Capsule
|
Interventional |
Not Applicable |
- Duke University
- National Institutes of Health (NIH)
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Change in craving score during Cue Exposure task
- Change in latency to smoke during Cue Exposure task
- Change in smoke intake during Cue Exposure task
|
120 |
All |
18 Years to 60 Years (Adult) |
NCT02551692 |
Pro00063505 1R01DA038442 |
|
January 2016 |
December 2018 |
March 2019 |
September 16, 2015 |
June 2, 2017 |
|
- Duke Medical Center
Durham, North Carolina, United States
|
21 |
NCT02737358 |
Recruiting |
N-acetylcysteine for Tobacco Use Disorder |
- Nicotine Dependence
- Smoking
|
- Drug: N-acetylcysteine (NAC)
- Other: Placebo
|
Interventional |
Phase 2 |
- Medical University of South Carolina
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Biochemically-verified abstinence from smoking on Days 1-3 of the protocol.
- Days to relapse to smoking
- 7-day point prevalence abstinence at the 8-week end-of-treatment visit
|
110 |
All |
18 Years to 65 Years (Adult) |
NCT02737358 |
Pro 00052793 R34DA042228 |
|
August 30, 2016 |
June 2019 |
August 2019 |
April 13, 2016 |
January 31, 2018 |
|
- Medical University of South Carolina
Charleston, South Carolina, United States
|
22 |
NCT03104634 |
Recruiting |
The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers |
|
- Drug: Aclidinium bromide/formoterol fumarate dihydrate
- Drug: Placebo
|
Interventional |
Phase 3 |
- McGill University Health Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Inspiratory pleural pressures at rest and throughout incremental exercise (cmH2O)
- Resting and exercise-induced changes in plasma natriuretic peptide concentrations (plasma concentration)
- Resting and dynamic lung volumes (end-inspiratory/end-expiratory lung volume)
- (and 5 more...)
|
40 |
All |
45 Years to 75 Years (Adult, Senior) |
NCT03104634 |
2017-2748 |
|
May 1, 2017 |
December 1, 2018 |
July 1, 2019 |
April 7, 2017 |
September 29, 2017 |
|
- McGill University Health Centre Research Institute
Montreal, Quebec, Canada
|
23 |
NCT02961309 |
Not yet recruiting |
A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking |
|
|
Interventional |
Phase 1 |
- Battelle Memorial Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Number of tobacco cigarettes smoked
- Latency to first tobacco cigarette smoked
- Mean puff topography of tobacco cigarettes smoked
- (and 2 more...)
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT02961309 |
BMI-73659 |
MJCIG |
March 2018 |
June 2018 |
June 2018 |
November 10, 2016 |
January 23, 2018 |
|
|
24 |
NCT02856581 |
Recruiting |
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes |
|
- Drug: Varenicline
- Drug: Placebo
- Other: Tobacco Cessation Counseling
|
Interventional |
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Pfizer
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
|
- Mortality
- Re-hospitalization
- Incidence of pulmonary complications
- (and 11 more...)
|
783 |
All |
18 Years and older (Adult, Senior) |
NCT02856581 |
A211401 NCI-2016-00438 |
|
September 29, 2017 |
February 2021 |
February 2022 |
August 5, 2016 |
April 9, 2018 |
|
- Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Fowler Family Center for Cancer Care
Jonesboro, Arkansas, United States - PCR Oncology
Arroyo Grande, California, United States - (and 262 more...)
|
25 |
NCT03235505 |
Not yet recruiting |
Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers |
- Smoking Cessation
- Electronic Cigarette
|
- Drug: Nicotine
- Drug: Varenicline Tartrate
- Behavioral: Motivational Interview
|
Interventional |
Phase 4 |
- Tuula Toljamo
- Lapland Central Hospital Rovaniemi Finland
- University of Oulu
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Smoking cessation during the follow-up visit at week 24
- Smoking cessation at any other study visit
- Reduce smoking at any study visit
|
450 |
All |
30 Years to 70 Years (Adult, Senior) |
NCT03235505 |
WI218780 |
EFFECT |
September 1, 2017 |
December 31, 2019 |
December 31, 2020 |
August 1, 2017 |
August 1, 2017 |
|
|
26 |
NCT01954966 |
Recruiting |
Progesterone and Brain Imaging Study |
- Nicotine Dependence
- Nicotine Withdrawal
|
- Drug: Progesterone
- Drug: Placebo
|
Interventional |
Phase 4 |
- University of Pennsylvania
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in Occipital Cortex GABA Pre and Post Placebo Administration
- Symptoms during nicotine abstinence
- Change from Baseline in Occipital Cortex GABA Pre and Post Progesterone Administration
|
150 |
All |
18 Years to 50 Years (Adult) |
NCT01954966 |
811940 K24DA030301 |
|
November 2010 |
May 2020 |
May 2021 |
October 7, 2013 |
February 27, 2018 |
|
- Penn Center for Women's Behavioral Wellness
Philadelphia, Pennsylvania, United States
|
27 |
NCT03204396 |
Recruiting |
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues |
- Glucagon-like Peptide-1
- Smoking Cessation
- Weight Change, Body
- Craving
|
- Drug: Dulaglutide
- Drug: 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
|
Interventional |
Phase 2 |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Point prevalence abstinence rate at week 12
- Change in Body weight
|
256 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03204396 |
2017-00286 |
SKIP |
June 26, 2017 |
March 31, 2020 |
March 31, 2020 |
July 2, 2017 |
July 2, 2017 |
|
- Universitätsspital Basel
Basel, Switzerland
|
28 |
NCT02595749 |
Recruiting |
Effects of Intranasal Oxytocin on Cigarette Smoking |
- Nicotine Dependence
- Tobacco Smoking
|
- Drug: Oxytocin
- Drug: Placebo
|
Interventional |
Phase 4 |
- University of Southern California
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Smoking Lapse Analogue Task (delay score)
- Brief Questionnaire of Smoking Urges
- Systolic blood pressure
- (and 4 more...)
|
30 |
All |
18 Years to 40 Years (Adult) |
NCT02595749 |
HS-15-00657 |
|
July 2016 |
July 2018 |
July 2018 |
November 3, 2015 |
April 19, 2017 |
|
- USC Health, Emotion and Addiction Laboratory
Los Angeles, California, United States
|
29 |
NCT03342027 |
Not yet recruiting |
Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya |
- Hiv
- Opioid Dependence
- Smoking Cessation
|
- Drug: Bupropion
- Behavioral: Positively smoke free
- Other: Brief advice to quit smoking
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
300 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03342027 |
HP-00077523 |
|
September 1, 2018 |
December 31, 2023 |
December 31, 2023 |
November 14, 2017 |
January 23, 2018 |
|
|
30 |
NCT02351167 |
Recruiting |
Genetically Informed Smoking Cessation Trial |
|
- Drug: Combination NRT (Nicotine patch, Nicotine lozenge)
- Drug: Varenicline
- Drug: Placebo
- Behavioral: Intensive smoking counseling
|
Interventional |
Phase 4 |
- Washington University School of Medicine
- National Institutes of Health (NIH)
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- 7-day point prevalence quit rate
- Continuous Abstinence
- Number of days to lapse and relapse
- (and 3 more...)
|
720 |
All |
21 Years and older (Adult, Senior) |
NCT02351167 |
201305128 1R01DA038076-01A1 |
GISC |
July 1, 2013 |
July 1, 2019 |
July 1, 2019 |
January 30, 2015 |
November 20, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
31 |
NCT02240069 |
Recruiting |
Wood Smoke Interventions in Native American Populations |
- Respiratory; Disorder, Functional, Impaired
- Respiratory Infection Other
|
- Behavioral: Education (Tx1)
- Device: Air Filtration Unit Treatment (Tx2)
- Device: Placebo Intervention (Tx3)
|
Interventional |
Not Applicable |
- University of Montana
- National Institute of Environmental Health Sciences (NIEHS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Improving measures of pulmonary function
- Respiratory symptoms and infections
- Wood smoke exposure
|
188 |
All |
55 Years and older (Adult, Senior) |
NCT02240069 |
IRB 218-12 R01ES022583 |
EldersAIR |
November 2014 |
June 2019 |
June 2020 |
September 15, 2014 |
October 18, 2017 |
|
- University of Montana
Missoula, Montana, United States
|
32 |
NCT02968602 |
Recruiting |
Minocycline and Tobacco Craving in Smokers With Schizophrenia |
|
- Drug: Minocycline
- Other: Placebo
|
Interventional |
Phase 4 |
- University of Maryland
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Questionnaire for Smoking Urges-Brief
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT02968602 |
HP-00072110 4K23DA034034-04 |
|
March 31, 2017 |
April 2018 |
April 2018 |
November 18, 2016 |
May 4, 2017 |
|
- Maryland Psyciatric Research Center
Catonsville, Maryland, United States
|
33 |
NCT02975297 |
Recruiting |
Exenatide Once Weekly for Smoking Cessation |
|
- Drug: Exenatide
- Drug: NRT
- Behavioral: Counseling
- Drug: Placebo
|
Interventional |
Phase 1 Phase 2 |
- The University of Texas Health Science Center, Houston
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Abstinence as assessed by self-report
- Abstinence as assessed by expired carbon monoxide (CO) levels
- Post-quit craving as assessed by the Questionnaire of Smoking Urges
- (and 2 more...)
|
90 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02975297 |
HSC-MS-17-0802 CCTS Research Scholar Award |
|
July 2016 |
June 2019 |
June 2019 |
November 29, 2016 |
December 6, 2017 |
|
- The University of Texas Health Science Center at Houston
Houston, Texas, United States
|
34 |
NCT02905734 |
Recruiting |
Nicotine Replacement Therapy in Nicotine-dependent Arrestees |
|
- Drug: Nicotine patch
- Other: placebo patch
|
Interventional |
Phase 4 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Perceived quality of detention in police cells at 8 hours following treatment administration
- Rating of desire to smoke after treatment administration
- Rating of intention to quit smoking after treatment administration;
- (and 2 more...)
|
1000 |
All |
18 Years to 76 Years (Adult, Senior) |
NCT02905734 |
P 140703 |
SUBNIGAV |
January 3, 2017 |
April 3, 2019 |
October 3, 2019 |
September 19, 2016 |
May 3, 2017 |
|
- Médecine légale - Hôpital Jean Verdier
Bondy, France
|
35 |
NCT03416621 |
Not yet recruiting |
Project Q Pilot: Smoking Cessation for Light Smokers |
|
- Other: Cognitive behavioral cessation counseling
- Drug: Counseling and placebo drug intervention
- Drug: Counseling and active drug intervention
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Feasibility determined by visit completion
- Acceptability determined by patient satisfaction
- validated cessation
|
75 |
All |
18 Years to 65 Years (Adult) |
NCT03416621 |
Pro00089760 |
|
April 24, 2018 |
August 2018 |
August 2018 |
January 31, 2018 |
April 23, 2018 |
|
- Duke University Medical Center - Cancer Prevention, Detection and Control
Durham, North Carolina, United States
|
36 |
NCT03083353 |
Recruiting |
Enhancing Cue Exposure Treatment for Smoking Reduction With Isradipine |
|
- Drug: Isradipine
- Behavioral: CET
- Drug: Placebos
|
Interventional |
Early Phase 1 |
- University of Texas at Austin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Craving Intensity to Smoking Cues
- Abstinence: Number of abstinence days
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT03083353 |
2016-09-0150 |
|
April 1, 2017 |
December 2018 |
December 2018 |
March 20, 2017 |
May 2, 2017 |
|
- University of Texas at Austin
Austin, Texas, United States
|
37 |
NCT03059563 |
Not yet recruiting |
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users |
- Dopamine D2/3 Receptor Availability
- Cognitive Function
- Methamphetamine Abuse
|
- Drug: Varenicline
- Other: Placebo
|
Interventional |
Phase 1 |
- University of California, Los Angeles
- Tarzana Treatment Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Dopamine D2-type receptor availability
- Sustained attention
- Working memory
- (and 8 more...)
|
36 |
All |
18 Years to 50 Years (Adult) |
NCT03059563 |
17-000445 |
|
April 2017 |
April 2019 |
April 2019 |
February 23, 2017 |
February 23, 2017 |
|
|
38 |
NCT02460900 |
Recruiting |
Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke |
|
- Drug: Varenicline
- Behavioral: Positively Smoke Free
- Drug: Placebo
- Behavioral: Standard of Care
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 7-day point prevalence abstinence
|
300 |
All |
18 Years to 65 Years (Adult) |
NCT02460900 |
HP-00062925 |
|
July 2016 |
July 2020 |
July 2020 |
June 3, 2015 |
January 25, 2018 |
|
- University of Maryland Medical Center, Midtown Campus
Baltimore, Maryland, United States
|
39 |
NCT02851901 |
Recruiting |
Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial |
|
|
Interventional |
Phase 3 |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Number of Adverse Events
- Number of subjects that quit smoking
|
187 |
All |
18 Years and older (Adult, Senior) |
NCT02851901 |
UPCC 05912 |
|
May 2012 |
May 2018 |
|
August 2, 2016 |
August 2, 2016 |
|
- Northwestern University
Chicago, Illinois, United States - Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
40 |
NCT02378714 |
Recruiting |
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers |
- Nicotine Dependence
- Major Depressive Disorder
|
- Drug: Varenicline
- Behavioral: BASC
- Behavioral: Standard treatment
|
Interventional |
Phase 4 |
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Point-prevalence abstinence
- Prolonged abstinence
- Continuous abstinence
- (and 2 more...)
|
576 |
All |
18 Years and older (Adult, Senior) |
NCT02378714 |
STU00100303 1R01CA184211-01A1 |
|
June 2015 |
August 2019 |
August 2020 |
March 4, 2015 |
September 13, 2017 |
|
- Northwestern University
Chicago, Illinois, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
41 |
NCT02348203 |
Recruiting |
Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers |
- Current Every Day Smoker
- Multiple Pulmonary Nodules
- Tobacco Smoking
- Tobacco Use Disorder
|
- Drug: Aspirin
- Other: Laboratory Biomarker Analysis
- Other: Placebo
- Drug: Zileuton
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Changes in a smoking-related gene expression signature score in the nasal epithelium of current smokers after acetylsalicylic acid (ASA) and zileuton intervention
- Impact of ASA and zileuton on three lung cancer gene signatures (an 80-gene bronchial signature, a PI3K pathway gene signature and a nasal diagnostic gene signature)
- Change in the smoking-related gene expression signature
- (and 8 more...)
|
66 |
All |
18 Years and older (Adult, Senior) |
NCT02348203 |
NCI-2015-00061 N01-CN-2012-00031 1403269898 UAZ2013-02-01 N01CN00031 P30CA023074 |
|
January 13, 2016 |
January 31, 2019 |
|
January 28, 2015 |
March 19, 2018 |
|
- The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - Boston University School of Medicine
Boston, Massachusetts, United States
|
42 |
NCT03077724 |
Recruiting |
Fish Oil to Reduce Tobacco Use iN Expectant Mothers Study |
- Tobacco Use in Childbirth
- Smoking Cessation
- Pregnancy Related
|
- Drug: Fish oil
- Drug: Placebos
|
Interventional |
Phase 2 |
- Vanderbilt University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Cigarettes per day
- Fagerström Tolerance Questionnaire
- Point prevalence abstinence
|
40 |
Female |
18 Years to 45 Years (Adult) |
NCT03077724 |
161820 |
FORTUNE |
March 2, 2017 |
January 23, 2018 |
June 2018 |
March 13, 2017 |
January 25, 2018 |
|
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
|
43 |
NCT02271919 |
Recruiting |
Varenicline and Combined Nicotine Replacement Therapy (NRT) for Smoking Cessation |
|
- Drug: Varenicline
- Other: Placebo Patch
- Drug: Nicotine Patch
- (and 5 more...)
|
Interventional |
Phase 4 |
- M.D. Anderson Cancer Center
- NAL Pharmaceuticals
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
|
500 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02271919 |
2014-0213 NCI-2015-00610 RP150228 |
|
May 2015 |
May 2019 |
May 2019 |
October 22, 2014 |
September 15, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
44 |
NCT03492463 |
Not yet recruiting New |
The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products |
- Nicotine Dependence, Cigarettes
|
- Drug: Nicotine patch
- Other: Placebo patch
- Other: E-cigarettes
- Other: Non-nicotine e-cigarettes
|
Interventional |
Phase 2 |
- Duke University
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Basic Science
|
- Expired air carbon monoxide (CO) to assess recent smoking
- Cigarette use, assessed by self-report in daily dairies
- E-cigarette use, assessed by self-report in daily dairies
- Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
|
1600 |
All |
18 Years to 65 Years (Adult) |
NCT03492463 |
Pro00084132 P50DA027840-07 |
ENDS-Switch |
May 1, 2018 |
May 1, 2021 |
May 1, 2021 |
April 10, 2018 |
April 10, 2018 |
|
- Duke Center for Smoking Cessation
Durham, North Carolina, United States
|
45 |
NCT03262662 |
Recruiting |
EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking |
|
- Drug: Varenicline
- Behavioral: Brief smoking cessation counseling
|
Interventional |
Phase 3 |
- State University of New York at Buffalo
- National Cancer Institute (NCI)
- Pfizer
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Continuous abstinence
- Pre-quit reduction in smoking
|
320 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03262662 |
STUDY00000911 R01CA206193 |
EVarQuit |
September 2017 |
May 2021 |
August 2021 |
August 25, 2017 |
September 12, 2017 |
|
- University at Buffalo (SUNYBuffalo)
Buffalo, New York, United States
|
46 |
NCT03365362 |
Not yet recruiting |
A Trial of Directly Observed and Long-term Varenicline |
- Tobacco Use Disorder
- Opioid-use Disorder
|
- Drug: Long-Term Varenicline
- Drug: Short-Term Varenicline
- Behavioral: Directly Observed Therapy
- Behavioral: Self Administered Therapy
|
Interventional |
Phase 4 |
- Albert Einstein College of Medicine, Inc.
- National Institutes of Health (NIH)
- Pfizer
- National Institute on Drug Abuse (NIDA)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Initial abstinence
- Time to lapse
- Time to relapse
- (and 4 more...)
|
450 |
All |
18 Years and older (Adult, Senior) |
NCT03365362 |
2016-6688 R01DA042813 |
|
June 2018 |
September 2021 |
January 2022 |
December 7, 2017 |
April 18, 2018 |
|
- Albert Einstein College of Medicine of Yeshiva University
Bronx, New York, United States
|
47 |
NCT03497299 |
Not yet recruiting New |
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia |
- Tobacco Use Disorder
- Schizophrenia
- Cognitive Functioning
- Craving
|
- Device: Active rTMS (20Hz)
- Device: Sham rTMS
|
Interventional |
Phase 2 |
- Centre for Addiction and Mental Health
- Yale University
- Oregon State University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to Smoking Lapse (TTL)
- Smoking Topography
- Spatial Delayed Response (SDR)/Visuospatial Working Memory (VSWM) Task
|
80 |
All |
18 Years to 55 Years (Adult) |
NCT03497299 |
003-2017 |
|
July 1, 2018 |
August 31, 2022 |
August 31, 2022 |
April 13, 2018 |
April 17, 2018 |
|
|
48 |
NCT02028871 |
Recruiting |
Intranasal Insulin for Weight Management During Smoking Cessation |
- Tobacco Abstinence Syndrome
|
- Drug: Intranasal Insulin
- Drug: Placebo
|
Interventional |
Phase 2 |
- Ajna Hamidovic
- University of New Mexico
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- amount eaten in taste test
- subjective measure of appetite
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT02028871 |
120700 |
|
July 2014 |
July 2016 |
October 1, 2017 |
January 7, 2014 |
July 28, 2017 |
|
- UNM College of Pharmacy
Albuquerque, New Mexico, United States - UNM College of Pharmacy
Albuquerque, New Mexico, United States
|
49 |
NCT02918500 |
Recruiting |
Effect of Pre-op NRT on Peri-operative Complications and Long-term Abstinence: A Pilot Trial in Patients Undergoing CABG Surgery |
|
|
Interventional |
Phase 4 |
- Ottawa Heart Institute Research Corporation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Carbon monoxide (CO) confirmed abstinence at the time of surgery
- The effect of pre-operative NRT on perceived stress and symptoms of nicotine withdrawal at the time of surgery
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02918500 |
20160696-01H |
|
October 23, 2017 |
March 2020 |
March 2021 |
September 29, 2016 |
November 6, 2017 |
|
- University of Ottawa Heart Institute
Ottawa, Ontario, Canada
|
50 |
NCT02759185 |
Recruiting |
Study of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD |
- Posttraumatic Stress Disorder
|
- Drug: High THC Marijuana
- Drug: High CBD Marijuana
- Drug: High THC/high CBD marijuana
- Drug: Placebo marijuana
|
Interventional |
Phase 2 |
- Multidisciplinary Association for Psychedelic Studies
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in CAPS Global Severity Score from baseline to primary endpoint
- Change in CAPS Global Severity Score from baseline to secondary endpoint
|
76 |
All |
18 Years and older (Adult, Senior) |
NCT02759185 |
MJP-1 |
|
January 2, 2017 |
August 2018 |
January 2019 |
May 3, 2016 |
March 29, 2018 |
|
- Scottsdale Research Institute
Phoenix, Arizona, United States
|